MedTrace Logo

Nitrous Oxide for Major Depressive Disorder

NCT03932825 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2021-04-08

No results posted yet for this study

Summary

This study aims at investigating the persistence of antidepressant effect of Nitrous Oxide (N2O) for Treatment-Resistant Depression(TRD). The investigators also aim to assess the effect of N2O on the electroencephalograph, multimodal magnetic resonance imaging(MRI), blood cytokines, feces bacteria flora and neuropsychological performance in patients with TRD. The investigators further aim to identify the predictors of N2O's antidepressant effeect using the above techniques.

Conditions

Interventions

DRUG

Nitrous Oxide

An 1-hour session of inhaled nitrous oxide at concentrations of 50%.

DRUG

Placebo

An 1-hour session of mixed oxygen-air gas(inspired oxygen concentration \~50%)

Sponsors & Collaborators

  • Lingjiang Li

    lead OTHER

Principal Investigators

  • Lingjiang Li, MD · Mental Health Institute, the Second Xiangya Hospital of Central South University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-01
Primary Completion
2021-03-31
Completion
2021-03-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03932825 on ClinicalTrials.gov